Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence (NICE) to treat a broader group of multiple sclerosis (MS) patients.

The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

The medication, which will be rolled out to patients with relapsing-remitting MS, is thought to be the first in Europe to be taken at home on a widespread basis ...

A take-at-home tablet for multiple sclerosis (MS) is set to be more broadly rolled out on the NHS, potentially benefiting thousands of patients in England. The move will also “significantly free up ...

The health service is thought to be the first in Europe to widely rollout cladribine, also known as Mavenclad and made by Merck. It has been approved by the National Institute for Health and Care ...

The effort is designed to raise awareness of RMS — and which is the most common form of MS — as well as the treatment option of Mavenclad (cladribine) tablets, which are produced by the healthcare ...

Merck is looking for new assets as one of its key growth drivers, multiple sclerosis drug Mavenclad, will face patent expiry in 2026. The German company’s goal is to achieve a 50-50 split ...

The pharma unit mainly relies on cancer drug Erbitux and multiple sclerosis treatment Mavenclad for growth, with the latter facing patent expiration starting in 2026. The health-care business ...